This article brings new evidence related to the potential use of MyBP-C as a biomarker in HF, particularly in comparison to established markers like NT-proBNP and hs-TnI, and its relevance in differentiating HF from other causes of dyspnea. This evidence concerns the gene NPPB and hydrops fetalis.